EPS growth, with buybacks, dividends and deleveraging driving 10%+ yield. Read the latest analysis on the stock here.

Today's newsletter is presented by addressSD.com. Aloha, La Jolla!, La Jolla Village News newsletter host It’s ...

Gov. Youngkin announced $6.2M in GO Virginia grants to fund 10 projects that expand workforce training, aviation maintenance ...

Ascidian Therapeutics and Forge Biologics have partnered to advance the development and manufacturing of ACDN-01.

Client programs using CHOMax follow platform-defined workflows and phase-appropriate practices across the development lifecycle.

Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three ...

Paris, Jan. 06, 2026 (GLOBE NEWSWIRE) -- 88% reduction in urinary incontinence episodes in patients with neurogenic bladder sustained through ...

Ascidian Therapeutics ("Ascidian"), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge ...

Russia-aligned UAC-0184 abuses Viber messages to deliver Hijack Loader and Remcos RAT in espionage attacks on Ukrainian ...

Q2 2026 Earnings Call Transcript January 6, 2026 AAR Corp. beats earnings expectations. Reported EPS is $1.18, expectations ...

Janine Hauck doesn't know which tick gave her anaplasmosis and Lyme disease. She just remembers the fatigue, weakness and ...

Today's AI agents are a primitive approximation of what agents are meant to be. True agentic AI requires serious advances in reinforcement learning and complex memory.